94 related articles for article (PubMed ID: 24933975)
1. [Efficiency of ursodeoxycholic acid therapy in non-alcoholic fatty liver disease associated with metabolic syndrome].
Avalueva EB; Tkachenko EI; Skazyvaeva EV; Ivanov SV; Orishak EA; Lapinskiĭ IV
Eksp Klin Gastroenterol; 2013; (11):26-30. PubMed ID: 24933975
[TBL] [Abstract][Full Text] [Related]
2. An open-label randomized control study to compare the efficacy of vitamin e versus ursodeoxycholic acid in nondiabetic and noncirrhotic Indian NAFLD patients.
Parikh P; Ingle M; Patel J; Bhate P; Pandey V; Sawant P
Saudi J Gastroenterol; 2016; 22(3):192-7. PubMed ID: 27184636
[TBL] [Abstract][Full Text] [Related]
3. The treatment with ursodeoxycholic acid in elderly patients affected by NAFLD and metabolic syndrome: a case-control study.
Troisi G; Crisciotti F; Gianturco V; D'Ottavio E; Lo Iacono C; Formosa V; Bernardini S; Bellomo A; Marigliano B; Marigliano V
Clin Ter; 2013; 164(3):203-7. PubMed ID: 23868620
[TBL] [Abstract][Full Text] [Related]
4. Ursodeoxycholyl Lysophosphatidylethanolamide modifies aberrant lipid profiles in NAFLD.
Pathil A; Liebisch G; Okun JG; Chamulitrat W; Schmitz G; Stremmel W
Eur J Clin Invest; 2015 Sep; 45(9):925-31. PubMed ID: 26108973
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of non-alcoholic steatohepatitis (NASH). A comparative study of ursodeoxycholic acid and alpha-tocopherol. A preliminary report].
Bernal-Reyes R; Escudero RB
Rev Gastroenterol Mex; 2002; 67(2):70-5. PubMed ID: 12214337
[TBL] [Abstract][Full Text] [Related]
6. Weight reduction and ursodeoxycholic acid in subjects with nonalcoholic fatty liver disease. A double-blind, placebo-controlled trial.
Méndez-Sánchez N; González V; Chávez-Tapia N; Ramos MH; Uribe M
Ann Hepatol; 2004; 3(3):108-12. PubMed ID: 15505596
[TBL] [Abstract][Full Text] [Related]
7. Clinical effect of the extract of TCM Fructus akebiae combined with ursodeoxycholic acid on nonalcoholic fatty liver disease.
Hongguang J; Xingjie H; Mingliang J; Yun L; Tongjian L; Jingmo Y; Liang L; Lifang Z
Pak J Pharm Sci; 2019 Jan; 32(1(Special)):433-437. PubMed ID: 30852481
[TBL] [Abstract][Full Text] [Related]
8. [UDCA in the treatment of nonalcoholic fatty liver disease].
Grigor'eva IN
Eksp Klin Gastroenterol; 2011; (11):79-85. PubMed ID: 22629725
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis.
Ratziu V; de Ledinghen V; Oberti F; Mathurin P; Wartelle-Bladou C; Renou C; Sogni P; Maynard M; Larrey D; Serfaty L; Bonnefont-Rousselot D; Bastard JP; Rivière M; Spénard J;
J Hepatol; 2011 May; 54(5):1011-9. PubMed ID: 21145828
[TBL] [Abstract][Full Text] [Related]
10. [UDCA in the treatment of nonalcoholic fatty liver disease].
Grigor'eva IN
Eksp Klin Gastroenterol; 2011; (9):125-31. PubMed ID: 22629789
[TBL] [Abstract][Full Text] [Related]
11. Ursodeoxycholic acid improves insulin sensitivity and hepatic steatosis by inducing the excretion of hepatic lipids in high-fat diet-fed KK-Ay mice.
Tsuchida T; Shiraishi M; Ohta T; Sakai K; Ishii S
Metabolism; 2012 Jul; 61(7):944-53. PubMed ID: 22154323
[TBL] [Abstract][Full Text] [Related]
12. Ursodeoxycholyl lysophosphatidylethanolamide improves steatosis and inflammation in murine models of nonalcoholic fatty liver disease.
Pathil A; Mueller J; Warth A; Chamulitrat W; Stremmel W
Hepatology; 2012 May; 55(5):1369-78. PubMed ID: 22183915
[TBL] [Abstract][Full Text] [Related]
13. [Condition of the intestinal tract microbiocenosis in patients with nonalcoholic fatty liver disease and the methods of its correction].
Kuchmin AN; Rezvan VV; Evsiukov KB; Fomin AA; Karshieva AV; Butikov VP
Voen Med Zh; 2010 Jun; 331(6):20-6. PubMed ID: 20731092
[TBL] [Abstract][Full Text] [Related]
14. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.
Lindor KD; Kowdley KV; Heathcote EJ; Harrison ME; Jorgensen R; Angulo P; Lymp JF; Burgart L; Colin P
Hepatology; 2004 Mar; 39(3):770-8. PubMed ID: 14999696
[TBL] [Abstract][Full Text] [Related]
15. [Approaches to the treatment of patients with climacteric disorders complicated with menopausal metabolic syndrome with cholestasis].
Gavrilova NP; Seliverstov PV; Tatarova NA; Radchenko VG
Eksp Klin Gastroenterol; 2014; (8):34-40. PubMed ID: 25911910
[TBL] [Abstract][Full Text] [Related]
16. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
[TBL] [Abstract][Full Text] [Related]
17. Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment.
Ersöz G; Günşar F; Karasu Z; Akay S; Batur Y; Akarca US
Turk J Gastroenterol; 2005 Sep; 16(3):124-8. PubMed ID: 16245220
[TBL] [Abstract][Full Text] [Related]
18. Is vitamin e or ursodeoxycholic acid a valid treatment option for nonalcoholic fatty liver disease in 2016?
Beaton MD; Al-Judaibi B
Saudi J Gastroenterol; 2016; 22(3):169-70. PubMed ID: 27184632
[No Abstract] [Full Text] [Related]
19. In patients with non-alcoholic fatty liver disease, metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not.
Younossi ZM; Otgonsuren M; Venkatesan C; Mishra A
Metabolism; 2013 Mar; 62(3):352-60. PubMed ID: 22999011
[TBL] [Abstract][Full Text] [Related]
20. Study of prevalence of nonalcoholic fatty liver disease (NAFLD) in type 2 diabetes patients in India (SPRINT).
Kalra S; Vithalani M; Gulati G; Kulkarni CM; Kadam Y; Pallivathukkal J; Das B; Sahay R; Modi KD
J Assoc Physicians India; 2013 Jul; 61(7):448-53. PubMed ID: 24772746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
